| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 09/16/2010 | US20100234448 In vivo production of small interfering rnas that mediate gene silencing |
| 09/16/2010 | US20100234447 Modulation of glucagon receptor expression |
| 09/16/2010 | US20100234300 A purified pro-cytolytic peptide; used to treat localized and metastatic prostate cancer; administered intratumorally and/or intraprostatically |
| 09/16/2010 | US20100234294 Identification of new isoforms of the mhc-class i specific receptor cd160 and uses thereof |
| 09/16/2010 | US20100234293 Novel Neurotrophic Factors |
| 09/16/2010 | US20100234290 Stabilized Insulin-like Growth Factor Polypeptides |
| 09/16/2010 | US20100233819 Robo: a novel family of polypeptides and nucleic acids |
| 09/16/2010 | US20100233814 Bacterial strains with improved plasmid stability |
| 09/16/2010 | US20100233810 In vivo production of small interfering rnas that mediate gene silencing |
| 09/16/2010 | US20100233809 Cytotoxic ribonuclease variants |
| 09/16/2010 | US20100233808 Liver tissue source |
| 09/16/2010 | US20100233804 Generation of pluripotent stem cells using recombinant proteins |
| 09/16/2010 | US20100233785 Novel methods and interferon deficient substrates for the propagation of viruses |
| 09/16/2010 | US20100233783 Novel method for protein purification |
| 09/16/2010 | US20100233762 Thermostable y-family polymerases and chimeras |
| 09/16/2010 | US20100233760 Protein Production in Microorganisms of the Phylum Labyrinthulomycota |
| 09/16/2010 | US20100233759 Method for production of polypeptide |
| 09/16/2010 | US20100233758 Protein increasing cell infectivity of herpes simplex virus and use thereof |
| 09/16/2010 | US20100233735 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 09/16/2010 | US20100233726 Tandem fluorescent protein constructs |
| 09/16/2010 | US20100233722 Methods for determining the biological effect and/or activity of r pharmaceutical compositions based on their effect on the methylation status of the DNA |
| 09/16/2010 | US20100233711 Gene encoding labyrinthin, a marker for cancer |
| 09/16/2010 | US20100233692 Fluorescently labeled fusion protein for assaying adenosine triphosphate |
| 09/16/2010 | US20100233690 Use of genes identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer |
| 09/16/2010 | US20100233685 Two-Color Fluorescent Reporter for Alternative Pre-MRNA Splicing |
| 09/16/2010 | US20100233676 High affinity fluorochrome binding peptides |
| 09/16/2010 | US20100233242 Engineered proteins, and methods of making and using |
| 09/16/2010 | US20100233215 IMMUNOTHERAPY BY USING CELL CAPABLE OF CO-EXPRESSING TARGET ANTIGEN AND CD1d AND PULSED WITH CD1d LIGAND |
| 09/16/2010 | US20100233213 Recombinant BCG Strains with Enhanced Ability to Escape the Endosome |
| 09/16/2010 | US20100233210 Subgenomic replicons of the flavivirus dengue |
| 09/16/2010 | US20100233209 Chikungunya virus infectious clones and uses therefor |
| 09/16/2010 | US20100233203 Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against recombinant antigen in mva vaccines |
| 09/16/2010 | US20100233202 Novel viral vector |
| 09/16/2010 | US20100233200 Vector encoding therapeutic polypeptide and safety elements to clear transduced cells |
| 09/16/2010 | US20100233186 Novel receptor that binds ctla-8 |
| 09/16/2010 | US20100233175 Antibodies relating to pivkaii and uses thereof |
| 09/16/2010 | US20100233173 Multispecific epitope binding proteins and uses thereof |
| 09/16/2010 | US20100233170 Fully human antibodies against N-Cadherin |
| 09/16/2010 | US20100233169 Methods for treating obesity using fibroblast growth factor-Like polypeptides |
| 09/16/2010 | US20100233165 Internalizing human monoclonal antibodies targeting prostate cancer cells in situ |
| 09/16/2010 | US20100233154 Targeted binding agents directed to heparanase and uses thereof 463 |
| 09/16/2010 | US20100233152 Use of HMGB proteins and nucleic acids that code therefor |
| 09/16/2010 | US20100233143 Parthenogenic Activation of Human Oocytes for the Production of Human Embryonic Stem Cells |
| 09/16/2010 | US20100233142 Stem Cells Derived from Uniparental Embryos and Methods of Use Thereof |
| 09/16/2010 | US20100233141 Compositions And Methods For The Delivery Of Biologically Active RNAs |
| 09/16/2010 | US20100233127 Targeted vectors for cancer immunotherapy |
| 09/16/2010 | US20100233126 Polypeptide |
| 09/16/2010 | US20100233087 Cyp1b1 nucleic acids and methods of use |
| 09/16/2010 | US20100233079 Dual Variable Domain Immunoglobulins and Uses Thereof |
| 09/16/2010 | DE102009043743A1 Zellspezifisch wirksame Moleküle auf Grundlage von siRNA sowie Applikationskits zu deren Herstellung und Verwendung Cell-specific molecules on the basis of effective siRNA application kits, and to their preparation and use |
| 09/16/2010 | CA2755301A1 Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy |
| 09/16/2010 | CA2755300A1 A polynucleotide and polypeptide sequence and methods thereof |
| 09/16/2010 | CA2755245A1 Compositions and methods for the delivery of biologically active rnas |
| 09/16/2010 | CA2755234A1 Apparatus for integrated real-time nucleic acid analysis, and method for detecting a target nucleic acid using same |
| 09/16/2010 | CA2754945A1 Biological materials and uses thereof |
| 09/16/2010 | CA2754906A1 Antigen presenting cell targeted vaccines |
| 09/16/2010 | CA2754900A1 Humanized pcrv antibody having anti-pseudomonal activity |
| 09/16/2010 | CA2754862A1 Anti-cd40 antibodies and uses thereof |
| 09/16/2010 | CA2754851A1 Method for improving the yield of a polypeptide |
| 09/16/2010 | CA2754764A1 Antigen presenting cell targeted cancer vaccines |
| 09/16/2010 | CA2754743A1 Antigen presenting cell targeted anti-viral vaccines |
| 09/16/2010 | CA2754603A1 Non-integrating retroviral vector vaccines |
| 09/16/2010 | CA2754591A1 Generation, expression and characterization of the humanized k33n monoclonal antibody |
| 09/16/2010 | CA2754539A1 Antibody molecules having binding specificity for human il-13 |
| 09/16/2010 | CA2754470A1 Mesophilic and thermophilic organisms modified to produce acrylate, and methods of use thereof |
| 09/16/2010 | CA2754387A1 Pregastric esterase and derivatives thereof |
| 09/16/2010 | CA2754056A1 Mirac proteins |
| 09/16/2010 | CA2754043A1 Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes |
| 09/16/2010 | CA2752044A1 Drought tolerant plants and methods involving genes encoding type c3hc4 ring finger zinc-finger family polypeptides |
| 09/16/2010 | CA2751301A1 Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines |
| 09/15/2010 | EP2228654A2 Diagnosis and prevention of cancer cell invasion |
| 09/15/2010 | EP2228449A1 Ethanol production process, and yeast for ethanol production |
| 09/15/2010 | EP2228448A1 MU-1 member of the cytokine receptor family |
| 09/15/2010 | EP2228447A2 Cloning and characterizing of genes associated with long-term memory |
| 09/15/2010 | EP2228446A1 Secreted and transmembrane polypeptieds and nucleic acids encoding the same |
| 09/15/2010 | EP2228445A1 Fucose Transporter |
| 09/15/2010 | EP2228444A1 microRNA for diagnostic and therapeutic purposes in cardiovascular diseases |
| 09/15/2010 | EP2228443A1 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| 09/15/2010 | EP2228442A1 Recombinant type II restriction endonucleases, Mmel and related endonucleases and methods for producing the same |
| 09/15/2010 | EP2228440A1 Variants of beta-glucosidases |
| 09/15/2010 | EP2228389A2 Antibodies against vascular endothelial growth factor 2 |
| 09/15/2010 | EP2228386A1 Plants having enhanced yield-related traits and a method for making the same |
| 09/15/2010 | EP2228385A1 Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
| 09/15/2010 | EP2228384A1 Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
| 09/15/2010 | EP2227780A2 Genetic analysis |
| 09/15/2010 | EP2227693A2 Tle3 as a marker for chemotherapy |
| 09/15/2010 | EP2227549A1 Organic compounds |
| 09/15/2010 | EP2227548A1 Seed-preferred gene promoters from the castor plant |
| 09/15/2010 | EP2227547A1 Chimeric construct of mungbean yellow mosaic india virus (mymiv) and its uses thereof |
| 09/15/2010 | EP2227546A1 Mammalian expression vector |
| 09/15/2010 | EP2227485A2 Resistance gene and uses thereof |
| 09/15/2010 | EP2227236A2 Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| 09/15/2010 | EP2087117B1 New ketolases for the production of ketocarotenoids in tagetes |
| 09/15/2010 | EP1799823B9 Method for modulating the evolution of a polypeptide encoded by a nucleic acid sequence |
| 09/15/2010 | EP1706497B1 Two-component rna virus- derived plant expression system |
| 09/15/2010 | EP1688491B1 Novel plasmids and utilization thereof |
| 09/15/2010 | EP1629100B1 Archaeon expression system |
| 09/15/2010 | EP1572976B1 Modulating immune responses |
| 09/15/2010 | EP1543838B1 Feline infectious peritonitis vaccine |
| 09/15/2010 | EP1533381B1 Adenovirus vector |